Dobrosmyslov IA - Search Results

1

[Alterations of the complement system in patients with catastrophic antiphospholipid syndrome].

Dem'ianova KA, Kozlovskaia NL, Shilov EM, Bobrova LA, Kozlov LV, Sorokin IuD, Roshchupkina SV, Nikiforova NV, Dobrosmyslov IA, Romanova MD. Dem'ianova KA, et al. Among authors: dobrosmyslov ia. Ter Arkh. 2014;86(6):30-7. Ter Arkh. 2014. PMID: 25095653 Russian.

2

[The role of balanced low-protein diet in inhibition of predialysis chronic kidney disease progression in patients with systemic diseases].

Milovanov IuS, Lysenko LV, Milovanova LIu, Dobrosmyslov IA. Milovanov IuS, et al. Among authors: dobrosmyslov ia. Ter Arkh. 2009;81(8):52-7. Ter Arkh. 2009. PMID: 19799201 Clinical Trial. Russian.

3

[Experience with active vitamin D metabolites in phosphorus-calcium metabolic disorders in patients with predialysis chronic kidney disease].

Milovanova LIu, Dobrosmyslov IA, Milovanov IuS. Milovanova LIu, et al. Among authors: dobrosmyslov ia. Ter Arkh. 2014;86(6):52-6. Ter Arkh. 2014. PMID: 25095656 Clinical Trial. Russian.

4

[Mechanisms of phosphorus and calcium homeostatic disorders in the development of cardiovascular events in patients with chronic renal diseases. The role of fibroblast growth factor 23 and Klotho].

Milovanova LIu, Kozlovskaia LV, Milovanov IuS, Bobkova IN, Dobrosmyslov IA. Milovanova LIu, et al. Among authors: dobrosmyslov ia. Ter Arkh. 2010;82(6):66-72. Ter Arkh. 2010. PMID: 20731116 Review. Russian.

5

[Effects of keto/amino acids and a low-protein diet on the nutritional status of patients with Stages 3B-4 chronic kidney disease].

Milovanova SY, Milovanov YS, Taranova MV, Dobrosmyslov IA. Milovanova SY, et al. Among authors: dobrosmyslov ia. Ter Arkh. 2017;89(6):30-33. doi: 10.17116/terarkh201789630-33. Ter Arkh. 2017. PMID: 28745686 Clinical Trial. Russian.

6

Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.

Milovanova LY, Dobrosmyslov IA, Milovanov YS, Taranova MV, Kozlov VV, Milovanova SY, Kozevnikova EI. Milovanova LY, et al. Among authors: dobrosmyslov ia. Ter Arkh. 2018 Jun 20;90(6):48-54. doi: 10.26442/terarkh201890648-54. Ter Arkh. 2018. PMID: 30701904

7

Quality of life of chronic kidney disease patients on renal replacement therapy.

Milovanov YS, Dobrosmyslov IA, Milovanova SY, Taranova MV, Milovanova LY, Fomin VV, Kozlov VV. Milovanov YS, et al. Among authors: dobrosmyslov ia. Ter Arkh. 2018 Jun 20;90(6):89-91. doi: 10.26442/terarkh201890689-91. Ter Arkh. 2018. PMID: 30701910 Review.

8

[The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].

Mukhin NA, Milovanov YS, Kozlovskaya LV, Dobrosmyslov IA, Milovanova LY. Mukhin NA, et al. Among authors: dobrosmyslov ia. Ter Arkh. 2016;88(4):41-45. doi: 10.17116/terarkh201688441-45. Ter Arkh. 2016. PMID: 27070162 Russian.

9

[Serum troponin-I as a marker of fibroblast growth factor-23 (FGF-23) cardiotoxic effect, in patients with chronic kidney disease].

Taranova MV, Milovanova LY, Kozlovskaya Lysenko LV, Milovanova SY, Androsova TV, Zubacheva DO, Lebedeva MV, Dobrosmyslov IA, Kozlov VV, Kuchieva AM, Li OA, Reshetnikov VA. Taranova MV, et al. Among authors: dobrosmyslov ia. Ter Arkh. 2019 Jun 15;91(6):85-92. doi: 10.26442/00403660.2019.06.000253. Ter Arkh. 2019. PMID: 36471601 Russian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters